Click to Download
PRESS RELEASE
6 May 2026
Press Release
Media Contacts:
IB Communications
ReiThera to Attend ASGCT 2026 in Boston, Showcasing Advanced Viral Vector Technologies
Rome, Italy 6th May 2026 - ReiThera, the Italian leading biotechnology company specialized in genetic vaccine platforms and advanced viral vector development, is pleased to announce its participation in the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting 2026, taking place in Boston, Massachusetts, from May 11 to May 15, 2026.
ReiThera will be exhibiting at Booth #1665, where attendees will have the opportunity to connect with the company’s scientific and business leadership team, including:
Stefano Colloca, Chief Executive Officer
Claudio Panzarella, Director of Business Development
Angelo Raggioli, Head of Technology Development
Francesca Bavasso, Business Development Manager
Michela Gentile, Cell Line Development Supervisor
Giuseppina Miselli, Upstream Process Development Supervisor
Francesca Vidali, Marketing & Communication
During the conference, ReiThera will present three scientific posters highlighting its latest innovations in viral vector technologies and manufacturing platforms:
“A Novel Oncolytic Gorilla-Derived Adenovirus (GRAd) with Natural Selective Replication in Cancer Cells” This work introduces a next-generation oncolytic vector with inherent tumor selectivity, opening new opportunities for cancer therapeutics.
“Integrated Platform for Recombinant MVA Generation, Scale-Up, and Purification Using a Suspension Duck Cell Line” A comprehensive platform designed to streamline MVA vector production with improved scalability and efficiency.
“ReiCell-AAV: Development and Optimization of a Scalable High-Yield Suspension Cell Line for AAV Vector Manufacturing” (in collaboration with Sartorius) This poster presents a novel suspension cell line enabling enhanced AAV production yields and industrial scalability.
“We are excited to return to ASGCT and engage with the global gene and cell therapy community,” said Stefano Colloca, CEO of ReiThera. “Our team looks forward to sharing our latest advancements and exploring new partnerships that can accelerate the development of innovative therapies.”
Attendees are invited to visit Booth #1665 to learn more about ReiThera’s technologies and discuss potential collaborations.
About ReiThera:
ReiThera Srl is a CDMO company dedicated to technology and process development and GMP manufacturing, providing support for the clinical translation of genetic vaccines and medicinal products for advanced therapies.
The company has extensive expertise in developing scalable processes for viral-vector manufacturing and a consolidated experience in GMP production of Adeno-Associated Vector (AAV), Lentivirus, Adeno Viral vector (AdV), Modified Vaccinia Ankara and Herpes Simplex Vector.
ReiThera's core manufacturing capacity is based in a state-of-the-art facility, which includes stirred-tank bioreactors at scales of 50L, 200L, 1000L, and 2000L, as well as fixed-bed bioreactors for cell growth in adherence. The GMP facility also comprises a filling suite and quality control laboratories.
ReiThera's headquarters, R&D laboratories, and GMP facilities are located in Rome, Italy. For more information, visit www.reithera.com